Windlas Biotech Limited

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about change in Management, with the appointment of Mr. Aashish Mehra and Mr. Soni Saran Singh as Additional Directors/Independent Directors, and the resignation of Mr. Vivek Dhariwal as Independent Director.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended September 30, 2026.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from October 1, 2026, till the expiry of 48 hours after the unaudited financial results of the Company for the quarter and half year ended September 30, 2026, becomes generally available information.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the schedule of analyst/institutional investor meetings to be held on September 7, 2026, where the company officials will discuss publicly available documents and no unpublished price sensitive information will be shared.

Windlas Biotech Limited

Windlas Biotech Limited has announced its Q1 FY27 earnings conference call transcript, highlighting a 18% YoY revenue growth to INR248 crores, driven by diversified business model, operational excellence, and customer trust. The company has also completed a buyback of INR47 crores and declared a dividend of INR13 crores.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the link of recording of its conference call on unaudited standalone financial results for the quarter ended June 30, 2026, which can be accessed via its website.

Windlas Biotech Limited

Windlas Biotech Limited has reported its Q1 FY27 financial results, with revenue from operations standing at Rs 248 crores, a growth of 18% YoY. Adjusted EBITDA stood at Rs 34 crores, a growth of 26% YoY, and adjusted PAT stood at Rs 25 crores, a growth of 37% YoY.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about Investor Presentation for Q1 FY27, highlighting its growth trajectory, diversified business model, operational excellence, and customer trust. The company reported its highest-ever quarterly revenue of ₹248 crore, representing 18% YoY growth.

Windlas Biotech Limited

Windlas Biotech Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹2,480.99 crore and total income at ₹2,532.12 crore.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the schedule of a conference call to discuss its financial performance for the quarter ended June 30, 2026. The conference call is scheduled to be held on August 11, 2026, at 11:30 A.M., IST. The company has also uploaded the conference call invite on its website.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the schedule of a conference call to discuss its financial performance for the quarter ended June 30, 2026. The conference call is scheduled to be held on August 11, 2026, at 11:30 P.M. IST. The company has also provided details of the conference call on its website.

Windlas Biotech Limited

Windlas Biotech Limited has submitted the combined voting results and scrutinizer's report for its 25th Annual General Meeting held on July 23, 2026. The meeting was conducted through video conferencing, and all resolutions were passed with the requisite majority. The company declared a final dividend of Rs. 6.30 per equity share for the financial year 2025-26 and appointed a new director in place of Mr. Hitesh Windlass, who is liable to retire by rotation.

Windlas Biotech Limited

Windlas Biotech Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 23, 2025, and informed the Exchange regarding voting results. All resolutions were passed at the AGM with requisite majority.

Windlas Biotech Limited

Windlas Biotech Limited held its 25th Annual General Meeting on July 23, 2026, where 63 members attended through video conferencing. The meeting adopted the audited financial statements, declared a final dividend of Rs. 6.30 per equity share, and appointed new directors. The voting results will be available on the company's website.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting, to be held virtually on July 14, 2026, where the company will discuss publicly available documents and not share any unpublished price-sensitive information.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about completion of despatch of Notice of 25th AGM and the Annual Report for FY26.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about record date/cut-off date for the purpose of AGM. The company has fixed July 16, 2026 as the cut-off date for ascertaining the names of members who will be entitled to cast their votes electronically during July 20, 2026 to July 22, 2026, and also during AGM in respect of business to be transacted at the aforesaid AGM and for the purpose of receiving dividend, if any.

Windlas Biotech Limited

Windlas Biotech Limited has informed the Exchange about the Annual General Meeting to be held on July 23, 2026, to consider and pass various resolutions, including the ratification of the remuneration of the Cost Auditors, appointment of a Director, and declaration of a Final Dividend.